{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:38:48Z","timestamp":1792201128123,"version":"4.4.0"},"reference-count":115,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.jconrel.2010.08.031","type":"journal-article","created":{"date-parts":[[2010,9,13]],"date-time":"2010-09-13T06:34:11Z","timestamp":1284359651000},"page":"147-159","source":"Crossref","is-referenced-by-count":260,"title":["Intravesical drug delivery: Challenges, current status, opportunities and novel strategies"],"prefix":"10.1016","volume":"148","author":[{"given":"Shruti","family":"GuhaSarkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2010.08.031_bb0005","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1152\/ajprenal.2000.278.6.F867","article-title":"Everything you wanted to know about the bladder epithelium but were afraid to ask","volume":"278","author":"Lewis","year":"2000","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"4","key":"10.1016\/j.jconrel.2010.08.031_bb0010","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1021\/mp060001j","article-title":"Recent advances in intravesical drug\/gene delivery","volume":"3","author":"Tyagi","year":"2006","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2010.08.031_bb0015","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.eururo.2006.08.025","article-title":"New frontiers in intravesical therapies and drug delivery","volume":"50","author":"Giannantoni","year":"2006","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jconrel.2010.08.031_bb0020","first-page":"61","article-title":"The mammalian urinary bladder: it's more than accommodating","volume":"1","author":"Lewis","year":"1986","journal-title":"News Physiol. Sci."},{"issue":"6","key":"10.1016\/j.jconrel.2010.08.031_bb0025","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1083\/jcb.200406025","article-title":"Roles of uroplakins in plaque formation, umbrella cell enlargement and urinary tract diseases","volume":"167","author":"Kong","year":"2004","journal-title":"J. Cell Biol."},{"issue":"18","key":"10.1016\/j.jconrel.2010.08.031_bb0030","doi-asserted-by":"crossref","first-page":"13716","DOI":"10.1016\/S0021-9258(17)36889-8","article-title":"Mammalian uroplakins: a group of highly conserved urothelial differentiation-related membrane proteins","volume":"269","author":"Wu","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2010.08.031_bb0035","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1083\/jcb.125.1.171","article-title":"Uroplakins Ia and Ib, two major differentiation products of bladder epithelium, belong to a family of four transmembrane domain (4TM) proteins","volume":"125","author":"Yu","year":"1994","journal-title":"J.Cell Biol."},{"key":"10.1016\/j.jconrel.2010.08.031_bb0040","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.urology.2008.01.028","article-title":"Urinary glycosaminoglycans as biomarker for urothelial injury: is it possible to discriminate damage from recovery?","volume":"72","author":"Soler","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.jconrel.2010.08.031_bb0045","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1078-1439(00)00074-0","article-title":"Glycosaminoglycan content of human bladders: a method of analysis using cold-cup biopsies","volume":"5","author":"Poggi","year":"2000","journal-title":"Urol. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2010.08.031_bb0050","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/ncpuro0672","article-title":"Mechanisms of disease: involvement of the urothelium in bladder dysfunction","volume":"4","author":"Birder","year":"2007","journal-title":"Nat. Clin. Pract. Urol."},{"key":"10.1016\/j.jconrel.2010.08.031_bb0055","doi-asserted-by":"crossref","first-page":"F489","DOI":"10.1152\/ajprenal.00467.2004","article-title":"More than just a barrier: urothelium as a drug target for urinary bladder pain","volume":"289","author":"Birder","year":"2005","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.jconrel.2010.08.031_bb0060","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(09)60491-8","article-title":"Bladder cancer","volume":"374","author":"Kaufman","year":"2009","journal-title":"Lancet"},{"issue":"6 Suppl. 1","key":"10.1016\/j.jconrel.2010.08.031_bb0065","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","article-title":"Bladder cancer: epidemiology, staging and grading, and diagnosis","volume":"66","author":"Kirkali","year":"2005","journal-title":"Urology"},{"issue":"4\u20135","key":"10.1016\/j.jconrel.2010.08.031_bb0070","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S1078-1439(99)00016-2","article-title":"Tumor, nodes, metastasis (TNM) classification of bladder cancer","volume":"4","author":"Richie","year":"1998","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.jconrel.2010.08.031_bb0075","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eursup.2008.08.002","article-title":"Epidemiology, staging, grading, and risk stratification of bladder cancer","volume":"7","author":"Colombel","year":"2008","journal-title":"Eur. Urol. Suppl."},{"key":"10.1016\/j.jconrel.2010.08.031_bb0080","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.eursup.2008.04.001","article-title":"Bladder cancer: a major public health issue","volume":"7","author":"Grasso","year":"2008","journal-title":"Eur. Urol. Suppl."},{"issue":"Suppl. 5","key":"10.1016\/j.jconrel.2010.08.031_bb0085","doi-asserted-by":"crossref","first-page":"v106","DOI":"10.1093\/annonc\/mdj963","article-title":"Challenges in the treatment of bladder cancer","volume":"17","author":"Kaufman","year":"2006","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.jconrel.2010.08.031_bb0090","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0302-2838(01)00026-4","article-title":"The EAU Working Group on Oncological Urology, Guidelines on Bladder Cancer","volume":"41","author":"Oosterlinck","year":"2002","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jconrel.2010.08.031_bb0095","first-page":"225","article-title":"Chapter 7: Bladder and Upper Tract Urothelial Cancer","author":"Konety","year":"2007"},{"issue":"6","key":"10.1016\/j.jconrel.2010.08.031_bb0100","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S0090-4295(96)00046-5","article-title":"Bladder wall fibrosis following intravesical mitomycin treatment for superficial bladder cancer","volume":"47","author":"Katz","year":"1996","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.jconrel.2010.08.031_bb0105","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.eursup.2006.12.005","article-title":"Bladder cancer: management and future directions","volume":"6","author":"Evans","year":"2007","journal-title":"Eur. Urol. Suppl."},{"issue":"5","key":"10.1016\/j.jconrel.2010.08.031_bb0110","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S1078-1439(00)00069-7","article-title":"Urinary diversion and bladder substitution in patients with bladder cancer","volume":"5","author":"Davidsson","year":"2000","journal-title":"Urol. Oncol."},{"issue":"6","key":"10.1016\/j.jconrel.2010.08.031_bb0115","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0022-5347(06)00264-3","article-title":"Complications of intravesical therapy for urothelial cancer of the bladder","volume":"175","author":"Koya","year":"2006","journal-title":"J. Urol."},{"issue":"Suppl. 3A","key":"10.1016\/j.jconrel.2010.08.031_bb0120","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.urology.2003.10.034","article-title":"Treatment of interstitial cystitis","volume":"63","author":"Chancellor","year":"2004","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.jconrel.2010.08.031_bb0125","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.maturitas.2009.09.016","article-title":"Interstitial cystitis\/bladder pain syndrome: an update","volume":"64","author":"Dasgupta","year":"2009","journal-title":"Maturitas"},{"key":"10.1016\/j.jconrel.2010.08.031_bb0130","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S1569-9056(03)00034-4","article-title":"The interstitial cystitis syndrome: intravesical and oral treatment","volume":"2","author":"Kurth","year":"2003","journal-title":"Eur. Urol. Suppl."},{"issue":"6","key":"10.1016\/j.jconrel.2010.08.031_bb0135","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bpobgyn.2005.08.004","article-title":"Painful bladder syndrome\/interstitial cystitis","volume":"19","author":"Rosamilia","year":"2005","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"10.1016\/j.jconrel.2010.08.031_bb0140","series-title":"Efficacy of Interstitial Cystitis Treatments","first-page":"47","volume":"4(2)","author":"Karsenty","year":"2006"},{"issue":"Suppl. 4A","key":"10.1016\/j.jconrel.2010.08.031_bb0145","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urology.2006.03.083","article-title":"Bladder defense molecules, urothelial differentiation, urinary biomarkers and interstitial cystitis","volume":"69","author":"Hurst","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.jconrel.2010.08.031_bb0150","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0531-5131(01)00433-2","article-title":"Use of glycosaminoglycans in the treatment of interstitial cystitis: a strategy to improve efficacy","volume":"1223","author":"Bhavanandan","year":"2001","journal-title":"Int. Congr. Ser."},{"issue":"5","key":"10.1016\/j.jconrel.2010.08.031_bb0155","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/j.juro.2009.07.013","article-title":"Restoring barrier function to acid damaged bladder by intravesical chondroitin sulfate","volume":"182","author":"Hauser","year":"2009","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.jconrel.2010.08.031_bb0160","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0302-2838(03)00418-4","article-title":"Intravesical infusion of resiniferatoxin by a temporary in situ drug delivery system to treat interstitial cystitis: a pilot study","volume":"45","author":"Lazzeri","year":"2004","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.jconrel.2010.08.031_bb0165","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.toxicon.2009.02.021","article-title":"Botulinum toxin in the treatment of OAB, BPH, and IC","volume":"54","author":"Smith","year":"2009","journal-title":"Toxicon"},{"issue":"4","key":"10.1016\/j.jconrel.2010.08.031_bb0170","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.eururo.2005.12.002","article-title":"Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study","volume":"49","author":"Giannantoni","year":"2006","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.jconrel.2010.08.031_bb0175","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0022-5347(01)65669-6","article-title":"Intravesical capsaicin for treatment of severe bladder pain: a randomized placebo controlled study","volume":"156","author":"Lazzeri","year":"1996","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.jconrel.2010.08.031_bb0180","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00005392-199907000-00002","article-title":"Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder","volume":"162","author":"Chancellor","year":"1999","journal-title":"J. Urol."},{"issue":"7","key":"10.1016\/j.jconrel.2010.08.031_bb0185","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1007\/s11095-008-9566-7","article-title":"Intravesical treatments of bladder cancer: review","volume":"25","author":"Shen","year":"2008","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.jconrel.2010.08.031_bb0190","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1067\/mcn.2001.117539","article-title":"Diagnosis and management of superficial bladder cancer","volume":"25","author":"Amling","year":"2001","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.jconrel.2010.08.031_bb0195","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1002\/1097-0142(19930901)72:5<1749::AID-CNCR2820720539>3.0.CO;2-8","article-title":"Intravesical 4'-epidoxorubicin (epirubicin) versus bacillus Calmette-Guerin: a controlled prospective study on the prophylaxis of superficial bladder cancer","volume":"72","author":"Melekos","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2010.08.031_bb0200","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0090-4295(96)00375-5","article-title":"BCG plus interferon alpha 2b in patients with superficial bladder cancer","volume":"48","author":"Stricker","year":"1996","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.jconrel.2010.08.031_bb0205","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1040-8428(03)00075-1","article-title":"Intravesical therapy of superficial bladder cancer","volume":"47","author":"Malmstr\u00f6m","year":"2003","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"2","key":"10.1016\/j.jconrel.2010.08.031_bb0210","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.eururo.2008.10.016","article-title":"Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer","volume":"55","author":"Calabr\u00f2","year":"2009","journal-title":"Eur. Urol."},{"issue":"Suppl. 2","key":"10.1016\/j.jconrel.2010.08.031_bb0215","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0959-8049(00)00076-9","article-title":"Paclitaxel and carboplatin in bladder cancer: recent developments","volume":"36","author":"Vaughn","year":"2000","journal-title":"Eur. J. Cancer"},{"issue":"Suppl. 2","key":"10.1016\/j.jconrel.2010.08.031_bb0220","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0959-8049(00)00080-0","article-title":"Gemcitabine and cisplatin in locally advanced and\/or metastatic bladder cancer","volume":"36","author":"Von der Maase","year":"2000","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.jconrel.2010.08.031_bb0225","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.eururo.2006.05.035","article-title":"Improving efficacy of intravesical chemotherapy","volume":"50","author":"Gasi\u00f3n","year":"2006","journal-title":"Eur. Urol."},{"issue":"1-3","key":"10.1016\/j.jconrel.2010.08.031_bb0230","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0168-3659(01)00488-6","article-title":"Clinical aspects of drug delivery to tumors","volume":"78","author":"Au","year":"2002","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2010.08.031_bb0235","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0090-4295(99)00463-X","article-title":"Intravesical therapy for bladder cancer","volume":"55","author":"Kamat","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.jconrel.2010.08.031_bb0240","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.urology.2006.03.069","article-title":"Drug delivery systems in urology-getting \u201csmarter\u201d","volume":"68","author":"Farokhzad","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.jconrel.2010.08.031_bb0245","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2010.08.031_bb0250","doi-asserted-by":"crossref","first-page":"F886","DOI":"10.1152\/ajprenal.1996.271.4.F886","article-title":"Permeability properties of the intact mammalian bladder epithelium","volume":"271","author":"Negrete","year":"1996","journal-title":"Am. J. Physiol. Renal Fluid Electrolyte Physiol."},{"issue":"2","key":"10.1016\/j.jconrel.2010.08.031_bb0255","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.eururo.2007.04.065","article-title":"Nanotechnology and its relevance to the urologist","volume":"52","author":"Gommersall","year":"2007","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.jconrel.2010.08.031_bb0260","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.surneu.2003.09.036","article-title":"Introduction to nanotechnology and its applications to medicine","volume":"61","author":"Silva","year":"2004","journal-title":"Surg. Neurol."},{"issue":"1","key":"10.1016\/j.jconrel.2010.08.031_bb0265","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.urolonc.2007.03.017","article-title":"New frontiers in nanotechnology for cancer treatment","volume":"26","author":"Alexis","year":"2008","journal-title":"Urol. Oncol.: Seminars and Original Investigations"},{"issue":"8, Suppl. 1","key":"10.1016\/j.jconrel.2010.08.031_bb0270","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S1369-7021(05)71034-8","article-title":"Targeted cancer nanotherapy","volume":"8","author":"Kim","year":"2005","journal-title":"Mater. Today"},{"issue":"3","key":"10.1016\/j.jconrel.2010.08.031_bb0275","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.yexmp.2008.12.004","article-title":"Nanoparticle-based targeted drug delivery","volume":"86","author":"Singh","year":"2009","journal-title":"Exp. Mol. Pathol."},{"issue":"5","key":"10.1016\/j.jconrel.2010.08.031_bb0280","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1158\/1078-0432.CCR-07-1441","article-title":"Therapeutic nanoparticles for drug delivery in cancer","volume":"14","author":"Cho","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.jconrel.2010.08.031_bb0285","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S1461-5347(99)00171-6","article-title":"Liposomes, micelles and microemulsions as new delivery systems for cytotoxic alkaloids","volume":"2","author":"Cortesi","year":"1999","journal-title":"Pharm. Sci. Technolo. Today"},{"issue":"11","key":"10.1016\/j.jconrel.2010.08.031_bb0290","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.tips.2009.08.004","article-title":"Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer","volume":"30","author":"Malam","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2010.08.031_bb0295","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S0090-4295(02)02281-1","article-title":"Intravesical liposome administration\u2013a novel treatment for hyperactive bladder in the rat","volume":"61","author":"Fraser","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.jconrel.2010.08.031_bb0300","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/01.ju.0000102360.11785.d7","article-title":"Urodynamic and immunohistochemical evaluation of intravesical capsaicin delivery using thermosensitive hydrogel and liposomes","volume":"171","author":"Tyagi","year":"2004","journal-title":"J. Urol."},{"key":"10.1016\/j.jconrel.2010.08.031_bb0305","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0022-5347(17)40248-5","article-title":"The development of liposomes containing interferon alpha for the intravesical therapy of human superficial bladder cancer","volume":"143","author":"Frangos","year":"1990","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.jconrel.2010.08.031_bb0310","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.juro.2009.03.083","article-title":"Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin a delivery using liposomes","volume":"182","author":"Chuang","year":"2009","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.jconrel.2010.08.031_bb0315","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jconrel.2009.10.002","article-title":"Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy","volume":"142","author":"Pradhan","year":"2010","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2010.08.031_bb0320","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jconrel.2009.10.023","article-title":"Evaluation of pH-responsive liposomes containing amino acid-based zwitterionic lipids for improving intracellular drug delivery in vitro and in vivo","volume":"142","author":"Obata","year":"2010","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.jconrel.2010.08.031_bb0325","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.addr.2007.04.008","article-title":"Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles","volume":"59","author":"Wong","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2010.08.031_bb0330","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ejps.2009.04.008","article-title":"Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin","volume":"37","author":"Subedi","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2010.08.031_bb0335","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jconrel.2005.02.028","article-title":"Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice","volume":"105","author":"Reddy","year":"2005","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2010.08.031_bb0340","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.biomaterials.2008.09.014","article-title":"The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma","volume":"30","author":"Xu","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2010.08.031_bb0345","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.nano.2006.04.009","article-title":"Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems","volume":"2","author":"Reis","year":"2006","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2010.08.031_bb0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-5173(01)00691-3","article-title":"Biomedical applications of collagen","volume":"221","author":"Lee","year":"2001","journal-title":"Int. J. Pharmaceut."},{"key":"10.1016\/j.jconrel.2010.08.031_bb0355","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1021\/js970246a","article-title":"Transferrin conjugates of doxorubicin: synthesis, characterization, cellular uptake, and in vitro efficacy","volume":"87","author":"Kratz","year":"1998","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2010.08.031_bb0360","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","article-title":"Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles","volume":"132","author":"Kratz","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2010.08.031_bb0365","doi-asserted-by":"crossref","first-page":"7677","DOI":"10.1158\/1078-0432.CCR-04-1443","article-title":"Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy","volume":"10","author":"Lu","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2010.08.031_bb0370","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijpharm.2009.04.045","article-title":"Optimization of epirubicin nanoparticles using experimental design for enhanced intravesical drug delivery","volume":"376","author":"Chang","year":"2009","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2010.08.031_bb0375","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jconrel.2009.11.012","article-title":"Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes","volume":"143","author":"Gaucher","year":"2010","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2010.08.031_bb0380","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejpb.2008.09.011","article-title":"In vivo investigation of tolerance and antitumor activity of cisplatin-loaded PLGA-mPEG nanoparticles","volume":"71","author":"Mattheolabakis","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.jconrel.2010.08.031_bb0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.colsurfb.2009.09.001","article-title":"Biodegradable polymeric nanoparticles based drug delivery systems","volume":"75","author":"Kumari","year":"2010","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"5","key":"10.1016\/j.jconrel.2010.08.031_bb0390","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0169-409X(02)00046-7","article-title":"Prospects for cationic polymers in gene and oligonucleotide therapy against cancer","volume":"54","author":"Merdan","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2010.08.031_bb0395","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/j.addr.2005.09.019","article-title":"Dendrimer biocompatibility and toxicity","volume":"57","author":"Duncan","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.jconrel.2010.08.031_bb0400","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejpb.2008.09.023","article-title":"Dendrimers as versatile platform in drug delivery applications","volume":"71","author":"Svenson","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2010.08.031_bb0405","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S1359-6446(01)01757-3","article-title":"Poly(amidoamine) PAMAM dendrimers: from biomimicry to drug delivery and biomedical applications","volume":"6","author":"Esfand","year":"2001","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2010.08.031_bb0410","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1021\/bc9600630","article-title":"In vitro gene delivery by degraded polyamidoamine dendrimers","volume":"7","author":"Tang","year":"1996","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2010.08.031_bb0415","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1021\/bc0499127","article-title":"Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy","volume":"15","author":"Patri","year":"2004","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2010.08.031_bb0420","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1389-1723(04)70146-2","article-title":"Mechanism of enhancement effect of dendrimer on transdermal drug permeation through polyhydroxyalkanoate matrix","volume":"96","author":"Wang","year":"2003","journal-title":"J. Biosci. Bioeng."},{"issue":"3","key":"10.1016\/j.jconrel.2010.08.031_bb0425","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1748-0132(07)70084-1","article-title":"Magnetic nanoparticles for drug delivery","volume":"2","author":"Arruebo","year":"2007","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2010.08.031_bb0430","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00280-003-0597-9","article-title":"Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers","volume":"51","author":"Leakakos","year":"2003","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.jconrel.2010.08.031_bb0435","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.biomaterials.2007.08.050","article-title":"Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors","volume":"29","author":"Chertok","year":"2008","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2010.08.031_bb0440","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.urolonc.2007.03.019","article-title":"Emerging use of nanoparticles for the therapeutic ablation of urologic malignancies","volume":"26","author":"Stern","year":"2008","journal-title":"Urol. Oncol.: Seminars and Original Investigations"},{"issue":"31","key":"10.1016\/j.jconrel.2010.08.031_bb0445","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.1016\/j.biomaterials.2009.08.008","article-title":"Antiangiogenic properties of silver nanoparticles","volume":"30","author":"Gurunathan","year":"2009","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.jconrel.2010.08.031_bb0450","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.biotechadv.2009.11.007","article-title":"Bioconjugated quantum dots for cancer research: present status, prospects and remaining issues","volume":"28","author":"Biju","year":"2010","journal-title":"Biotechnol. Adv."},{"issue":"1","key":"10.1016\/j.jconrel.2010.08.031_bb0455","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jconrel.2008.10.014","article-title":"Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs","volume":"134","author":"Tan","year":"2009","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2010.08.031_bb0460","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.nano.2008.04.003","article-title":"Carbon nanotubes as functional excipients for nanomedicines: II. Drug delivery and biocompatibility issues","volume":"4","author":"Foldvari","year":"2008","journal-title":"Nanomedicine"},{"issue":"30","key":"10.1016\/j.jconrel.2010.08.031_bb0465","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1016\/j.biomaterials.2009.07.025","article-title":"Targeted delivery and controlled release of doxorubicin to cancer cells using modified single wall carbon nanotubes","volume":"30","author":"Zhang","year":"2009","journal-title":"Biomaterials"},{"issue":"11","key":"10.1016\/j.jconrel.2010.08.031_bb0470","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.addr.2005.07.001","article-title":"The basics and underlying mechanisms of mucoadhesion","volume":"57","author":"Smart","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2010.08.031_bb0475","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0378-5173(01)00979-6","article-title":"Design and evaluation of a mucoadhesive therapeutic agent delivery system for postoperative chemotherapy in superficial bladder cancer","volume":"235","author":"Eroglu","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2010.08.031_bb0480","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0378-5173(01)00748-7","article-title":"The study of drug release from microspheres adhered on pig vesical mucosa","volume":"224","author":"Burjak","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2010.08.031_bb0485","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejps.2005.02.003","article-title":"Permeability of pig urinary bladder wall: the effect of chitosan and the role of calcium","volume":"25","author":"Kerec","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"issue":"8","key":"10.1016\/j.jconrel.2010.08.031_bb0490","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1248\/bpb.29.1685","article-title":"Permeability of pig urinary bladder wall: time and concentration dependent effect of chitosan","volume":"29","author":"Kerec Kos","year":"2006","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jconrel.2010.08.031_bb0495","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijpharm.2008.12.015","article-title":"Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of mitomycin C to bladder tumors","volume":"371","author":"Bilensoy","year":"2009","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.jconrel.2010.08.031_bb0500","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.urology.2007.07.056","article-title":"Use of a sulfated chitosan derivative to reduce bladder inflammation in the rat","volume":"70","author":"Jordan","year":"2007","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.jconrel.2010.08.031_bb0505","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jconrel.2007.12.014","article-title":"Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice","volume":"127","author":"Kim","year":"2008","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2010.08.031_bb0510","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jconrel.2009.06.015","article-title":"Hydrotropic oligomer-conjugated glycol chitosan as a carrier of paclitaxel: synthesis, characterization, and in vivo biodistribution","volume":"140","author":"Saravanakumar","year":"2009","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2010.08.031_bb0515","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jconrel.2007.11.018","article-title":"Injectable chitosan hydrogels for localised cancer therapy","volume":"126","author":"Ta","year":"2008","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.jconrel.2010.08.031_bb0520","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1023\/B:PHAM.0000026436.62869.9c","article-title":"Sustained intravesical drug delivery using thermosensitive hydrogel","volume":"21","author":"Tyagi","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2010.08.031_bb0525","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ejps.2003.12.007","article-title":"In situ crosslinked biodegradable hydrogels loaded with IL-2 are effective tools for local IL-2 therapy","volume":"21","author":"Bos","year":"2004","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2010.08.031_bb0530","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijpharm.2007.07.026","article-title":"Injectable block copolymer hydrogels for sustained release of a PEGylated drug","volume":"348","author":"Yu","year":"2008","journal-title":"Int. J. Pharm."},{"issue":"10","key":"10.1016\/j.jconrel.2010.08.031_bb0535","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.addr.2009.04.010","article-title":"OncoGel (ReGel\/paclitaxel) \u2013 clinical applications for a novel paclitaxel delivery system","volume":"61","author":"Elstad","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2010.08.031_bb0540","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijpharm.2008.03.023","article-title":"A novel injectable local hydrophobic drug delivery system: biodegradable nanoparticles in thermo-sensitive hydrogel","volume":"359","author":"Gou","year":"2008","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.jconrel.2010.08.031_bb0545","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1040-8428(03)00076-3","article-title":"Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer: preliminary clinical experience","volume":"47","author":"Colombo","year":"2003","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jconrel.2010.08.031_bb0550","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.urology.2003.10.036","article-title":"Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer","volume":"63","author":"Gofrit","year":"2004","journal-title":"Urology"},{"issue":"17","key":"10.1016\/j.jconrel.2010.08.031_bb0555","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1016\/j.ejca.2008.07.038","article-title":"Hyperthermia adds to chemotherapy","volume":"44","author":"Issels","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jconrel.2010.08.031_bb0560","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.urology.2005.03.052","article-title":"Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model","volume":"66","author":"Horinaga","year":"2005","journal-title":"Urology"},{"issue":"7","key":"10.1016\/j.jconrel.2010.08.031_bb0565","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1471-4914(01)02088-3","article-title":"Gene therapy strategies for urological dysfunction","volume":"7","author":"Chancellor","year":"2001","journal-title":"Trends Mol. Med."},{"issue":"4","key":"10.1016\/j.jconrel.2010.08.031_bb0570","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0302-2838(02)00034-9","article-title":"Molecular aspects of bladder cancer IV: gene therapy of bladder cancer","volume":"41","author":"Ardelt","year":"2002","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.jconrel.2010.08.031_bb0575","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jconrel.2006.04.001","article-title":"In vitro and in vivo evaluation of novel cationic liposomes utilized for cancer gene therapy","volume":"113","author":"Serikawa","year":"2006","journal-title":"J. Control. Release"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365910007431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365910007431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T13:45:01Z","timestamp":1636465501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365910007431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":115,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0168365910007431"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2010.08.031","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}